


Key Points

- Outline components recommended by CDC for tracking, . reporting, and education
- Provide specific examples of parameters and metrics for tracking .
- Review strategies to report antimicrobial stewardship-related activities and outcomes
- Present methods to provide antimicrobial stewardship-related . education




The Performance Improvement Cycle Why we track Metrics



<section-header>

What Should be Tracked?



5

Tracking Antimicrobial Use

What to Track	How to Organize Data	How to Present Data
 Number of antimicrobial starts Antimicrobial days of therapy 	 Overall By antibiotic class By indication By prescriber By individual agent 	 Antibiotic starts per 1000 resident-days Days of therapy per 1000 resident-days


Why Per 1000 Resident Days?

- Converts the number of starts, or days of therapy to a rate
- Allows comparison between facilities of differing size
- Recommend to do by month

Example:

- \blacktriangleright (# of antibiotic starts in August \div # of resident days August) X 1000
- (# of days of therapy in August ÷ # of resident days August) X 1000





What Antimicrobials Should be Tracked?

- Search "CDC NHSN AUR MODULE"
- CDC document on how to submit antibiotic use data to NHSN AUR module
- Provides comprehensive list of antimicrobials
- Classifies as Anti-viral, Antibacterial, or Anti-fungal
- Provides Drug Class information
- Only lists generic names

Antimicrobial Use and Resistance (AUR) Module

Contents	
Antimicrobial Use and Resistance (AUR) Module	
Introduction	
1. Antimicrobial Use (AU) Option	
Introduction	
Requirements	
Data Analyses	
References	
Appendix A. Table of Instructions: Antimicrobial Use Option	
Appendix B. List of Antimicrobials	
Appendix C. Example Calculations of Antimicrobial Days	
Appendix D: List of SAARs ^a	
Appendix E: Antimicrobial Groupings for SAAR & Rate Table Calculations ⁴	
2. Antimicrobial Resistance (AR) Option	
Introduction	
Requirements	
Data Analyses	
Appendix F. List of Eligible Organisms for the NHSN AR Option	
Appendix G. Technical and Isolate Based Report Variables	
Appendix H. Denominator Data Variables	
Appendix I. NHSN AR Option Phenotype Definitions	
Appendix J. List of SRIRs and oSIRs	

ry 2023

Introduction

This module contains two options: one focused on antimicrobial use and the second on antimicrobial estatance. To participate in either option, facility personnel responsible for responsible material antimicrobial use AU) or resistance (AR) data to the National Healthcare Safety Network (NHSN) must coordinate with heir pharmary and/or laboratory information inforware providers to configure their system to generate tradeard formatted (Tels) to be imported into MRSN. The format provided for data submission follows not provide the system of the system of

9

https://w

Examples of Antimicrobials for Tracking

Antimicrobial Agent	Antimicrobial Category	Antimicrobial Class ^a	Antimicrobial Subclass*	Antimicrobial Agent	Antimicrobial Category	Antimicrobial Class ^a	Antimicrobial Subclass ^a
AMANTADINE	Anti-influenza	M2 ion channel		CEFPODOXIME	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation
		inhibitors		CEFPROZIL	Antibacterial	Cephalosporins	Cephalosporin 2 nd generation
AMIKACIN	Antibacterial	Aminoglycosides		CEFTAROLINE	Antibacterial	Cephalosporins	Cephalosporins with anti-
AMIKACIN LIPOSOMAL ^b	Antibacterial	Aminoglycosides					MRSA activity
AMOXICILLIN	Antibacterial	Penicillins	Aminopenicillin	CEFTAZIDIME	Antibacterial	Cephalosporins	Cephalosporin 3 rd generation
AMOXICILLIN/	Antibacterial	β-lactam/β-lactamase		CEFTAZIDIME/AVIBACTAM	Antibacterial	β-lactam/β-lactamase	
CLAVULANATE	Antibacterial	inhibitor combination				inhibitor combination	
AMPHOTERICIN B	Antifungal	Polyenes		CEFTOLOZANE/	Antibacterial	β-lactam/β-lactamase	
	-			TAZOBACTAM		inhibitor combination	
AMPHOTERICIN B LIPID	Antifungal	Polyenes		CEFTRIAXONE	Antibacterial	Cephalosporins	Cephalosporin 3rd generation
COMPLEX				CEFUROXIME	Antibacterial	Cephalosporins	Cephalosporin 2 nd generation
AMPHOTERICIN B	Antifungal	Polyenes		CEPHALEXIN	Antibacterial	Cephalosporins	Cephalosporin 1st generation
LIPOSOMAL				CHLORAMPHENICOL	Antibacterial	Phenicols	
AMPICILLIN	Antibacterial	Penicillins	Aminopenicillin	CIPROFLOXACIN	Antibacterial	Fluoroquinolones	
AMPICILLIN/	Antibacterial	β-lactam/β-lactamase		CLARITHROMYCIN	Antibacterial	Macrolides	
SULBACTAM		inhibitor combination					
ANIDULAFUNGIN	Antifungal	Echinocandins		CLINDAMYCIN	Antibacterial	Lincosamides	
AZITHROMYCIN	Antibacterial	Macrolides		COLISTIMETHATE	Antibacterial	Polymyxins	
				COLISTIN	Antibacterial	Polymyxins	
AZTREONAM	Antibacterial	Monobactams		DALBAVANCIN	Antibacterial	Glycopeptides	Lipoglycopeptides



Drugs That Should NOT Be Counted

- Antivirals
- Topical antifungals
 - Nystatin, clotrimazole, ketoconazole
- Topical antibiotics
 - Triple antibiotic, bacitracin, mupirocin
- Antibiotic-containing eye and ear drops/ointments
 Gentamicin, tobramycin, erythromycin
- Agents that work within GI tract or not absorbed
 Sulfasalazine, rifaximin
 - Exceptions: vancomycin PO, fidaxomicin
- Urinary tract antiseptic/analgesic
 Methenamine, phenazopyridine



Determining Antibiotic Starts

- Obtain data
 - Antibiotic dispense report from pharmacy
 - Quick/Easy to obtain, but may require some fixing (see example)
 - Antibiotic start log
 - More work upfront, but greater control over data



Determining Antibiotic Starts

Pharmacy Dispense Report Example

May Antibiotic Report

Product Name	Label Name	Days Supply	Quantity Dispensed	Date of Service	The ClassName
SULFAMETHOXAZOLE- TRIMETHOPRIM	SULFAMETHOXAZOLE- TWP DS TABLET	5	10	10/17/2016	SULFONAMIDES (SYSTEMIC)
CEPHALEXIN	CEPHALEXIN 500 MG CAPSULE	10	29	7/19/2016	CEPHALOSPOR
CEPHALEXIN	CEPHALEXIN 500 MG CAPSULE	10	29	7/19/2016	CEPHALOSPORI
CEPHALEXIN	CEPHALEXIN 250 MG CAPSULE	1	2	7/19/2016	CEPHALOSPORI
CEPHALEXIN	CEPHALEXIN 250 MG CAPSULE	1	2	7/19/2016	CEPHALOSPORI
CEFUROXIME	CEFUROXIME AXETIL 500 MG TAB	7	7	12/2/2016	CEPHALOSPOR
CEFUROXIME	CEFUROXIME AXETIL 250 MG TAB	4	4	12/2/2016	CEPHALOSPORI
CEFUROXINE	CEFUROXIME AXETIL 250 MG TAB	1	1	12/10/2016	CEPHALOSPORI
CEFPODOXIME PROXETIL	CEFPODOXINE 200 MG TABLET	7	14		CEPHALOSPOR

May Resident-Days = 450

- Remove agents that shouldn't be
- Calculate starts/1000 resident-days

Other Things to Consider

	Label Name	Days	Quantity Dispensed	Date of Service	ClassNam
SULFAMETHOXAZOLE- TRIMETHOPRIM	SULFANETHOXAZOLE- TMP DS TABLET	5	10		SULFONAMIDE (SYSTEMIC)
CEPHALEXIN	CEPHALEXIN 500 MG CAPSULE	10	29	7/19/2016	CEPHALOSPO
CEPHALEXIN	CEPHALEXIN 500 MG CAPSULE	10	29	7/19/2016	CEPHALOSPO
CEPHALEXIN	CEPHALEXIN 250 MG CAPSULE	1	2	7/19/2016	CEPHALOSPO
CEPHALEXIN	CEPHALEXIN 250 MG CAPSULE	1	2	7/19/2016	CEPHALOSPO
CEFUROXINE	CEFUROXIME AXETIL 500 MG TAB	7	7	12/2/2016	CEPHALOSPO
	CEFUROXIME AXETIL 250	4	4	12/2/2016	CEPHALOSPO
CEFUROXINE	MG TAB		1	12/10/2016	CEPHALOSPO
CEFUROXIME	CEFUROXINE AXETIL 250 MG TAB	1	ľ		
	CEFUROXINE AXETIL 250	1 7	14		CEPHALOSPO

Duplicate listing with same drug, dose, and duration

- - Need patient level data to confirm Charge to different insurance?
- Was any antibiotic ordered, dispensed, but not given?
 - Request pharmacy for drug crediting report if available Review antibiotic start log


Determining Antibiotic Days of Therapy

June Antibiotic Report


Product Name	Label Name	Days Supply	Quantity Dispensed	Date of Service	The ClassName
AMOXICILLN- CLAVULANATE POTASS	AMOX-CLAV 400-57 MG/5 ML SUSP	7	100	8/1/2016	PENCILLINS
CEFUROXIME	CEFUROXIME AXETIL 25 MG TAB	1	-	8/2/2016	CEPHALOSPORI
DOXYCYCLINE HYCLATE	HYCLATE 100 NG TAB	10	10	8/3/2016	TETRACYCLINE
CEPHALEXIN	CEPHALEXIN 500 MG CAPSULE	7	1	8/3/2016	CEPHALOSPORI
CEFUROXIME	CEFUROXINE AXETIL 25 MG TAB	9	18	8/3/2016	CEPHALOSPOR
DOXYCYCLINE HYCLATE	DOXYCYCLINE HYCLATE 100 MG TAB	7	14	8/3/2016	TETRACYCLINE
NITROFURANTOIN	NITROFURANTOIN MCR 100 MG CAP	1		8/3/2016	URNARY ANTI- INFECTIVES
NITROFURANTOIN MONO- MACRO	NITROFURANTON MONO MCR 100 MG	7	14	8/3/2016	URNARY ANTI- INFECTIVES
CEETRIA VONE	CEETRIA YOME 10 GM			0/4/2016	CERWAL OSDOR

June Resident-Days = 490


- Antibiotic dispensing report Antibiotic start log if duration recorded Remove drug that should not be counted (none)
- Sum up 'Days Supply' for all antibiotics or for specific classes
- All agents: 49 days Cephalosporins: 17 days Calculate days of therapy (DOT) per 1000 resident-days All = $\frac{49 \text{ days}}{490 \text{ resident-days}} * 1000 = 100$



Electronic Infection and Antibiotic Start Log using Microsoft Excel



Electronic Infection and Antimicrobial Start Log using Microsoft Excel



Self-Assessment Question #1

A resident was taking azithromycin and amoxicillin for 5 days for community-acquired pneumonia

- 1. What is the total number of antibiotic starts?
- 2. What is the total days of therapy?



Self-Assessment Question #2

A resident started Nitrofurantoin twice a day for 5 days starting the evening of September 30th, and finished the course on the morning of October 5th.

- 1. Does the start count for September, or October?
- 2. What are the total days of therapy for September?
- 3. What are the total days of therapy for October?



Why Track So Many Use Metrics?

Antibiotic Starts

Assess impact of initiatives that address when antibiotics are not appropriate

(e.g., asymptomatic bacteriuria)

Days of Therapy

- · Assess impact of interventions that shorten duration of therapy
- Better metric to monitor overall antibiotic use over time


Standardizing by Patient-Days

- · Account for variations in number of residents and lengths of stay
- · Allow within facility comparison over time
- Make between facility comparison possible



Tracking Process Measures – *Compliance with Clinical Assessment*

<u>What to Track</u>	How to Organize Data	How to Present Data
Was assessment tool used? (Y/N)	Overall (200 assessment performed)	% of time assessment tool used for an infection
Which tool was used? (UTI SBAR, RTI SBAR)	By type of infection (UTI, SSTI)	% of suspected infection met criteria before starting ABX
Were criteria met? (Y/N)	By unit (2 east, 2 west)	
Who assessed the resident? (Nurse A, Nurse B)	By person assessing resident (Nurse A, Nurse B)	



23

Tracking Process Measure – Prescribing Documentation

What to Track	 Antibiotic orders with dose, frequency, duration, indication documented
How to Organize Data	OverallBy prescribers
How to Present Data	 % of all antibiotic orders with required documentation % of antibiotic orders <u>from a specific prescriber</u> with required documentation
Logistics	 Capture data <u>before</u> getting missing info Request nurses to capture info for all new antibiotic orders

Tracking Process Measure – Antibiotic Selection Based on Guidelines

- Only if facility-specific treatment guidelines are available
 - Based on national guidelines, resistance pattern, prescriber preferences
 - Work with consultant pharmacists, medical directors to create
- What to track
 - Frequency guideline-recommended antibiotics are selected
 - Frequency the correct dose is selected
 - Frequency correct duration is prescribed
- · Capture data monthly or quarterly if antibiotic use is low
- Data can be from
 - Pharmacy
 - Antibiotic start/infection log
 - Indication MUST be documented for successful tracking




25

Tracking Outcome Measures – Antibiogram

- Antibiotic susceptibility patterns for specific organisms in a period
- Based on >30 isolates of an organism to increase statistical power
 - But >20 isolates acceptable per AHRQ
 - · Can increase isolates by increasing timespan (e.g., to 24 months)
- Should only base information on 1st positive culture from multiple consecutive positives
- If large number of positive cultures, can categorize antibiogram
 - By culture source (e.g., urine cultures)
 - By nursing units



Tracking Outcome Measures -- Antibiogram



- Things to consider
 - Does patient have history of UTI where culture data is available?
 - What is the most likely organism in UTI?
 - What is the antibiotic with the highest percent susceptibility?
 - Can antibiotic only be given PO? Is antibiotic readily available in NH?



Tracking Outcome Measures – Infection Rates of Specific Organisms

- NHSN tracking
 - MRSA (methicillin-resistant Staphylococcus aureus)
 - VRE (vancomycin-resistant enterococci)
 - ESBL (extend spectrum β-lactamase) Gram negative bacilli
 - CRE (carbapenem-resistant Enterobacteriaceae)
 - Clostridioides difficile infections
- Data can be standardized by
 - Patient–Days
 - Number of new admissions
- Why track them?
 - Direct consequences of the extent of antibiotic use AND infection control practices



Other Outcome Measures -Adverse Drug Events (ADR)

Rates of antibiotic-related adverse events •

- C difficile infections
- Diarrhea, loose stools unrelated to CDI
- Rash, hives
- Fluoroquinolones: Tendon rupture, hypo/hyperglycemia, confusion, seizure, neuropathy, others
- Requires careful review of clinical records to determine causality Þ
 - Naranjo adverse drug reaction probability scale¹
 - Classify causal relationship as definite, probable, possible, doubtful
- Request assistance from
 - Consultant pharmacist as part of monthly drug use evaluation
 - Medical director
 - Specific nurse caring for resident who experienced the ADR

Naranjo CA, et al. Clin Pharmacol Ther 1981:30:239-45.



Example of Tool for Evaluating ADR

[Facili	ty Logo]	Resi	ident Li	abel			inhibitors	Ceftazidime, Ceftibuten,	e, Cetprozil, Cettaroline, , Cettazidime-Avibactam, Ceftolozane-Tazobactam, , Cefuroxime, Cephadroxil,
	Adverse Drug Reaction Wo	orksheet					Carbapenems	Doripenem, Cilastatin, M	Ertapenem, Imipenem-
Evaluation Date:	Evaluated By: Dosing Begimen:	Date of Adv				No	Fluoroquinolone		n, Delafloxacin Levofloxacin,
Adverse Reaction: (Refer to a list of common adverse an	ntimicrobial reactions in Table 1 on the ne	ist page)					Macrolides	4.25.000.00	n, Clarithromycin,
Probability Reaction Related to Mee	dication (from the Naranjo Probability Sca	sie below)					Resources and	Erythromyci	in
Definite (2.9)	Probable (5-8) Possible (1-4	4) 🗆 Doubtful	(0)				Tetracyclines	Doxycycline,	, Minocycline, Tetracycline
Consequence of Adverse Reaction (check all that apply):						Sulfonamides	Sulfamethor	azole-Trimethoprim
No change-therapy cont Increased monitoring Oisability	Symptomatic medica Permanent Damage	i treatment	Therapy Correction Delayed	ve surgie	al proced	ure .			
Hospitalization	Other (specify):		- 68				Glycopeptides	Telavancin,	Vancomycin IV
Reviewer:		Date:				_	Others	Cindamaria	Metronidazole.
Are there previous CONCLUSIVE rep Advances of 2 or new last described loss Old the adverse reaction appear aft	means can be found in the Instature ter the suspected drug was administered?		+1	0	D D			information if an a	adverse drug reaction not listed
Old the advecte reaction improve w	al adda is a write 3 2 down the map among when the drug was discontinued or a speci	fic antagonist given?	+1	0	0		Category	Score Range	
Arrest pet l'interitet lessin at disperses Dist the adverse reaction reappears	when the drug was readministered?		+2	-1	0		Definite	2 9	
Arrest per l'investe lesses au disparent Did the adverse reaction reappear s Arrest au l'inclus anappear officient Are there allernative rauses (other		interted	+2	-1	0			29	e Interpretation Reaction 1) followed a re- had been established in b suspected drug; and 3) w
Annex on or Constitution tension or disappears DNS the adverse reaction reappears shown and reaction adappears offer day Are there alternative causes (other Annex on Constitution adappear when a p DNS the maximum causes are adapted	when the drug was readministered? An economics for experiences when the drug was on than the suspect drug) that could have a by near an evaluation over the the superior du facebo was stren?	interted	_				Probably		e Interpretation Reaction 1) followed a reaction had been established in b
Answer on Creation teaction realingueses Did the adverse reaction reagence drivers and reaction analysis of the Are there alternative causes (other design and the reaction reagence when a Did the reaction reagence when a discuss of the reaction reagence of the	when the drug was readministered? than the suspect drug? that could have co facebo was given? Another that is plante.	atoms aused the reaction? *	-1	+ 2	0			29	Interpretation Reaction 1) followed a re- had been established in b suspected drug; and 3) w Reaction 1) followed a re- response to the suspecter drug; 4) could not be reast
Arrow of Freeman and a mapping OW the adverse reaction reappoint are there afternative causes (other Old the reaction reappear when a p We the drug detected in throad or Was the reaction more severe when	where the drug was readoministered? there the surgect drug is that could have a there the surgect drug is that could have a particular an extension soften that the surgect du- facebox was given? Another the surgect of the surgect du- tication or convention attems because to an another surgects may a disk was intravened or lines servere when a disk was intravened or lines servere whence whence when a disk was int	e texic? down was decreased?	-1	+2	0			29	Interpretation Reaction 3) followed a me had been established in b suspected drug; and 3) w Reaction 3) followed a rm response to the suspected drug; 4) could not be reast state Reaction 1) followed a ten
An end of the advector transmission of the advector transmission of the transmission of the transmission of the reaction reagees when a provide the transmission of the reaction more severe when the transmission of the reaction more severe when the transmission of the protection of the protection more severe when the transmission of the transmission of the protection more severe when the transmission of the transmis	when the drug was readministerod? discretionalistic to support drug that could have co- than the support drug that could have co- facebo was given? development of the drug that could have co- there funds in concentrations known to be of or wardinauction and	etternet aused the reaction? e e toxic? dowr was decreased? evicus appose?	-1 -1 +1	+ 2 + 3 0	0 0 0		Probably Possible	29 5-8 1-4	Interpretation Reaction 3) followed a rm had been established in b suspected drug; and 3 w Reaction 3) followed a re response to the suspected drug; 4) could not be reasi state Reaction 3) followed a te to the suspected drug; 3)
And the advector exactlion respiperar And the advector exactlion respiperar And the reactlion respiperar when a structure of the reactlion respiperar when a Was the of the reactlion more severe when Did the reactlion more severe when Did the parameter have a summar react Did the parameter have a summar react Did the parameter have a summar react	where the drug, was readominister of ? than the suspect drug it has could have a particle of the suspect drug it has a more than the suspect drug it has could have a factor of the suspect factor of the suspect testing in concentrations brown to be or a maintenance maintenance of does not be a maintenance main difference of the suspect of the suspect of the subject of the suspect of the subject of the subject of the subject on the subject of the subject on the subject of the subject on the subject of the subject of the subject of the subject of the subject on the subject of the subject of the subject on the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the subject of the	e texic? concess deposer? concess deposer? tered readuration in the part	-1 -1 -1 -1	+2 +3 0	0 0 0		Probably	29	Interpretation Reaction 3) followed a me had been established in b suspected drug; and 3) w Reaction 3) followed a rm response to the suspected drug; 4) could not be reast state Reaction 1) followed a ten

Drug Class	Class Member	Common Adverse Reaction
Penicillins +/- Beta-Lactamase inhibitors	Ampicilin, Ampicilin-Subactam, Amoxicilin, Amoxicilin-Clavulanate, Clovacilin, Dicloxacilin, Nafcilin, Oxacilin, Penicilin, Piperacilin- Tazobactam	Nause, vomiting, diarrhea, C difficie infection, allergic reactions (including rash, hemolytic anemia), elevated serum creatinine, bone marrow suppression with long-term use, phiebits with IV therapy
Cephalosporins +/- Beta-Lactamase Inhibitors	Cefacior, Cefazoin, Cefdinir, Cefditoren, Cefepime, Cefixime, Cefotetan, Cefositin, Cefpadoaime, Cefazoil, Ceftaroline, Ceftazidime, Ceftazidime-Aubactam, Ceftibuten, Ceftolozane-Tazobactam, Ceftriaxone, Cefunosime, Cephadrosi, Cephalesin	Nausea, vomiting diarrhea, C attficile infection, allergic reactions (including rash, serum sickness), altered mental status
Carbapenems	Doripenem, Ertapenem, Imipenem- Cilastatin, Meropenem	Nausea, vomiting, diarrhea, C difficile infection, seizure
Fluoroquinolones	Ciprofloxacin, Delafloxacin Levofloxacin, Mosifloxacin	Disorientation, definium, agitation, seizure, hypo- or hyper-glycemia, peripheral neuropathy, tenden rupture, QT prolongation, nausea, vomiting, C difficile infection, increased in liver function tests, aortic dissection
Macrolides	Azithromycin, Clarithromycin, Erythromycin	Nausea, vomiting, elevation in liver function tests, reversible tinnitus or deafness, taste alteration, phlebitis with IV therapy
Tetracyclines	Doxycycline, Minocycline, Tetracycline	Nausea, vomiting, sunburn, esophageal ulcer, phlebitis with tV therapy, teeth discoloration
Sulfonamides	Sulfamethoxazole-Trimethoprim	Allergic reactions (rash, hives, drug fever, Steven Johnson Syndrome) headache, sumburn, hyperkalernia, worsen renal functions, bone marrow suppression, hemolytic anemia, hypoglycemia (especially with sulfoxylureas)
Glycopeptides	Telavancin, Vancomycin IV	Redman syndrome (flushing, itching, hypotension), worsened renal functions
Others	Clindamycin, Metronidazole, Nitrofurantoin	All: Naussea, vomiting: Clindamycin: disarrhea, C difficile infection, taste alterration; Metronidazole: disaffram reaction after alcohol (flushing, dyspines), taste alteration, peripheral neuropathy, confusion; Nitrofurantoin: interstitial pneumonitis especially with chronic use, hemplytic anemia

Definite	29	Reaction 1) followed a reasonable temporal requence after a drug or in which a toxic drug level had been established in body fluids or tissues; 2) followed a recognized response to the suspected drug; and 3) was confirmed by withdrawal but not by exposure to the drug
Probably	5-8	Reaction 1) followed a reasonable temporal sequence after a drug; 2) followed a recognized response to the suspected drug; 3) was confirmed by withdrawal but not by exposure to the drug; 4) could not be reasonably explained by the known characteristics of the patient's clinical state
Possible	1-4	Reaction 1) followed a temporal sequence after a drug; 2) possibly followed a recognized pattern to the suspected drug; 3) could be explained by characteristics of the patient's disease
Doubtful	0	Reaction was likely related to factors other than a drug


rse drug reactions. Clin Pharmacol Ther 1981:30:239-45

Other Antibiotic Use/Outcome Measures NOT Covered

- Defined daily dose (DDD) per 1000 resident-days
 - Requires more calculations
 - DDD definitions may not reflect how antibiotics are usually dosed
- Point prevalence survey
 - % residents receiving antibiotics on a single day
 - Easier to determine but does not inform overall use
- Antibiotic utilization ratio

 Total monthly DOT/total monthly resident-days
 - Represent average DOT in a single resident-day
- Antibiotic-related costs
 - Important from an administrative perspective
 - Costs fluctuate and may not represent overall use





Reporting Antimicrobial Stewardship Data Activities and Outcomes

- CDC recommends reporting tracked data to:
 - Clinical providers
 - Nursing staff
- ASAP experience from onsite visits
- Tracked data typically only available to a select few (e.g., QAPI)
- What good is it if no one knows about it!
 - Data can increase buy-in
 - Resistance rate may deter use
 - Rate of inappropriate UA/culture may improve use of assessment tool
 - Justify your existence in the facility



Reporting Antimicrobial Stewardship Activities and Outcomes

Who to report to

- Prescribers
- Nursing staff
- Selectively to residents/families

What to report


- Antibiotic use data (starts, DOT)
- Rates of specific infections
- Compliance to policy (met criteria before starting antibiotics)
- \$\$ spent on antibiotics

How to report

- Use existing system
 - Newsletter, QAPI report
- Frequency varies based on type and volume of information
- Annually for antibiogram, antibiotic spending
- Quarterly, semi-annually, or annually for other info


<section-header><section-header><section-header><section-header><section-header><section-header><section-header><text><text><section-header><section-header><section-header><section-header><text><text><text><text><section-header><section-header><section-header><section-header><section-header><text><text><section-header><text><section-header>

From: https://asap.nebraskamed.com/long-term-care/tools-templates-long-term-care/. Accessed 4/15/19.




Antimicrobial Stewardship Education

(Proliferiore)	Example of
[Facility Logo]	
FROM: [Executive Director, Medical Director, Director of Nursing, etc.]	ASP Education
DATE: [Date] RE: Antimicrobial Stewardship Program	
	Consequence of
Antibiotis are among the most commonly prescribed medications within long-term care facilities. However, misuse of antibiotiss can lead to undesirable outcomes including emergence of multidrug resistant pathogens, development of Clostridium difficile infections, adverse drug reactions, increased mortality, and higher costs.	misuse
As part of the continuing commitment to provide high quality care to all our residents, the leadership team of [listing name] has created an Antibiotic Stewardship Program (AD). This program will promote appropriate use of antibiotics in our facility. The overall goal of AD is to prevent undersize be outcomes instruct to antibiotics in mice heaterstime of two care. Increa. and durities of therapy.	What is ASP & Goal of ASP
Antibiotic use protocols and systems to monitor antibiotic use will be implemented to achieve ASP goals.	Program leaders
The ASP will be a part of the facility's infection Prevention and Control Program. Infection preventional will also a contart role and the locality is infection for the morean include Modelal Director. Denotor of humany Complete Talmanusci, col. The multidiorational team will regularly rower appropriateness of intibiotic course and make recommendations for Adjustment for particle where receivance and the or review entities protocol relative ta association and their correcting.	Specific ASP tasks
monitor and report patterns of antibiotic use and resistance; and provide education on responsible use of antibiotics.	🖉 Who is responsible
The success of this initiative requires the full participation and support of those who prescribe, preparely deminister, and neave antimicrobial therapy. The facility will provide adeutate staffing and resources to support the functions and goals of the AIP. AIP seam will engage prescribing providers, staff, residents, and resident families to ensure that antibiotic use prototoles can be implemented wroothly. Facility ladershap is confident that with the help of functions staff, support of prescribing providers, understanding of resident and multiles, and guidance of AIP team, we will improve quality of care and minimize untroward consequences of antibiots therapy.	




Resident/Family-Specific ASP Educations - Trifold Brochure





Antimicrobial Stewardship Education





- Tracking, reporting, and education are important core elements that have direct impact on antimicrobial use
- Tracking includes policy compliance, antibiotic use, antibiotic resistance, and infection rates
- Reporting should inform prescribers, staff, residents of ASP activities and outcomes
- Education should be target audience specific and include goals of ASP, appropriate antibiotic prescribing/use



Free Online Resources

- Nebraska ASAP (<u>asap.nebraskamed.com</u>)
- CDC (cdc.gov/longtermcare/prevention/antibioticstewardship.html)
- AHRQ (<u>ahrq.gov/nhguide/index.html</u>)
- University of Rochester (<u>rochesterpatientsafety.com/</u>)

